These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9353333)

  • 1. Inhibition of meizothrombin and meizothrombin(desF1) by heparin cofactor II.
    Han JH; Côté HC; Tollefsen DM
    J Biol Chem; 1997 Nov; 272(45):28660-5. PubMed ID: 9353333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in situ inhibition of prothrombinase-formed human alpha-thrombin and meizothrombin(des F1) by antithrombin III and heparin.
    Schoen P; Lindhout T
    J Biol Chem; 1987 Aug; 262(23):11268-74. PubMed ID: 3611110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity.
    Sheehan JP; Wu Q; Tollefsen DM; Sadler JE
    J Biol Chem; 1993 Feb; 268(5):3639-45. PubMed ID: 8429040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin.
    Nagase H; Enjyoji K; Minamiguchi K; Kitazato KT; Kitazato K; Saito H; Kato H
    Blood; 1995 Mar; 85(6):1527-34. PubMed ID: 7888673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
    Sheehan JP; Tollefsen DM; Sadler JE
    J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
    Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex.
    Maekawa H; Sato H; Tollefsen DM
    Thromb Res; 2000 Dec; 100(5):443-51. PubMed ID: 11150588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple active forms of thrombin. IV. Relative activities of meizothrombins.
    Doyle MF; Mann KG
    J Biol Chem; 1990 Jun; 265(18):10693-701. PubMed ID: 2355015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.
    Derechin VM; Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional characterization of recombinant human meizothrombin and Meizothrombin(desF1). Thrombomodulin-dependent activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI), platelet aggregation, antithrombin-III inhibition.
    Côté HC; Bajzar L; Stevens WK; Samis JA; Morser J; MacGillivray RT; Nesheim ME
    J Biol Chem; 1997 Mar; 272(10):6194-200. PubMed ID: 9045633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of heparin cofactor II anticoagulant activity.
    Bauman SJ; Church FC
    J Biol Chem; 1999 Dec; 274(49):34556-65. PubMed ID: 10574918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.
    Van Deerlin VM; Tollefsen DM
    J Biol Chem; 1991 Oct; 266(30):20223-31. PubMed ID: 1939083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation.
    Parker KA; Tollefsen DM
    J Biol Chem; 1985 Mar; 260(6):3501-5. PubMed ID: 3838315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II.
    Verhamme IM; Bock PE; Jackson CM
    J Biol Chem; 2004 Mar; 279(11):9785-95. PubMed ID: 14701814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin.
    Holland CA; Henry AT; Whinna HC; Church FC
    FEBS Lett; 2000 Nov; 484(2):87-91. PubMed ID: 11068038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II.
    Cooper ST; Rezaie AR; Esmon CT; Church FC
    Thromb Res; 2002 Jul; 107(1-2):67-73. PubMed ID: 12413592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin.
    Church FC; Meade JB; Treanor RE; Whinna HC
    J Biol Chem; 1989 Feb; 264(6):3618-23. PubMed ID: 2914965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides.
    Ofosu FA; Modi GJ; Hirsh J; Buchanan MR; Blajchman MA
    Ann N Y Acad Sci; 1986; 485():41-55. PubMed ID: 2436525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of meizothrombin as intermediate in factor Xa-catalyzed prothrombin activation.
    Rosing J; Zwaal RF; Tans G
    J Biol Chem; 1986 Mar; 261(9):4224-8. PubMed ID: 3753979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recombinant murine meizothrombin precursor, prothrombin R157A/R268A, inhibits thrombosis in a model of acute carotid artery injury.
    Shim K; Zhu H; Westfield LA; Sadler JE
    Blood; 2004 Jul; 104(2):415-9. PubMed ID: 15039280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.